24/7 Market News Snapshot 21 January, 2025 – Xilio Therapeutics, Inc. Common Stock (NASDAQ:XLO)

January 21, 2025

DENVER, Colo., 21 January, 2025 (247marketnews.com) – (NASDAQ:XLO) are discussed in this article.
Xilio Therapeutics, Inc. (XLO) is navigating a challenging market environment, opening at $1.17, with the current trading price reflecting a decline to $1.13, representing a 0.88% decrease. Trading activity has intensified, with volumes reaching 608.08K, indicative of increased market participation. Key support levels appear around $1.10, and any breach could signal further downward movement in share value. Investors are encouraged to remain vigilant, observing trading volumes and market conditions closely for cues on potential price movements.

Despite the stock’s volatility, Xilio is making significant strides in its clinical endeavors. The company has released promising preliminary results from its ongoing Phase 2 trial, which evaluates the combination of vilastobart (XTX101) and atezolizumab (Tecentriq®) for treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial targets heavily pre-treated patients and has reported an encouraging 27% preliminary response rate among those without liver metastases. Notable findings show substantial decreases in carcinoembryonic antigen (CEA) and circulating tumor DNA (ctDNA) levels, alongside improved clinical outcomes for responding patients.

Dr. Katarina Luptakova, Chief Medical Officer of Xilio, expressed optimism about these results, highlighting vilastobart’s unique mechanism as a potential breakthrough for patients who have not traditionally benefited from immunotherapy. The study, which involved 40 participants, demonstrated three confirmed partial responses and a disease control rate of 55%. Safety assessments suggest that the combination therapy maintains a favorable profile, with minimal immune-related adverse events.

The findings will be presented at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium, reinforcing the therapeutic relevance of vilastobart in addressing the substantial unmet needs of MSS CRC patients. Xilio continues to invest in this promising therapeutic area and anticipates offering further updates on the trial later this year.

Related news for (XLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.